RxSight (RXST) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
RxSight (RXST) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 13.80% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -27.18% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 14.80% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 73.85% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 12.92% |
| 10 | RxSight | 250.81 Mn | -153.43 Mn | - | -2.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.64% |
| Mar 31, 2026 | -93.94% |
| Dec 31, 2025 | -56.55% |
| Sep 30, 2025 | -54.88% |
| Jun 30, 2025 | -93.88% |
| Mar 31, 2025 | 10.00% |
| Dec 31, 2024 | -111.78% |
| Sep 30, 2024 | 48.95% |
| Jun 30, 2024 | 55.96% |
| Mar 31, 2024 | 31.12% |
| Dec 31, 2023 | -7.23% |
| Sep 30, 2023 | 26.18% |
| Jun 30, 2023 | 17.50% |
| Mar 31, 2023 | 24.91% |
| Dec 31, 2022 | 440.07% |
| Sep 30, 2022 | -32.71% |
| Jun 30, 2022 | -24.15% |
| Mar 31, 2022 | -158.57% |
| Dec 31, 2021 | -565.38% |
| Sep 30, 2021 | -314.80% |